Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy.

NCT03466827 is registered in ClinicalTrials.gov with Morten Mau-Soerensen as lead sponsor.

NCT NCT03466827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03466827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy.
Lead sponsor
Morten Mau-Soerensen
Phase
Phase 2
Overall status
Unknown status
Start date
October 12, 2017
Completion date
July 1, 2020
Enrollment
25 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced thymic epithelial tumour, thymoma